NASDAQ: DWTX
Dogwood Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for DWTX

Based on 1 analyst offering 12 month price targets for Dogwood Therapeutics Inc

Min Forecast
$12.00+1,011.11%
Avg Forecast
$12.00+1,011.11%
Max Forecast
$12.00+1,011.11%

Should I buy or sell DWTX stock?

Based on 1 analyst offering ratings for Dogwood Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DWTX stock forecasts and price targets.

DWTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-19

1 of 1

Forecast return on equity

Is DWTX forecast to generate an efficient return?

Company
N/A
Industry
43.27%
Market
164.09%

Forecast return on assets

Is DWTX forecast to generate an efficient return on assets?

Company
N/A
Industry
21.27%

DWTX earnings per share forecast

What is DWTX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.89-108.7%
Avg 2 year Forecast
-$0.73-107.16%
Avg 3 year Forecast
-$0.77-107.46%

DWTX revenue forecast

What is DWTX's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$9.6M+9,511%
DWTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DWTX revenue growth forecast

How is DWTX forecast to perform vs Biotechnology companies and vs the US market?

Company
331.05%
Industry
31.63%
Market
12.01%
DWTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DWTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DWTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DWTX$1.08$12.00+1,011.11%Buy
PLRX$0.66N/AN/A
ALDX$0.69$5.50+692.51%Buy
ELTX$1.43$13.67+855.73%Strong Buy
HYFT$0.91$5.00+451.27%Buy

Dogwood Therapeutics Stock Forecast FAQ

Is Dogwood Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DWTX) stock is to Buy DWTX stock.

Out of 1 analyst, 0 (0%) are recommending DWTX as a Strong Buy, 1 (100%) are recommending DWTX as a Buy, 0 (0%) are recommending DWTX as a Hold, 0 (0%) are recommending DWTX as a Sell, and 0 (0%) are recommending DWTX as a Strong Sell.

If you're new to stock investing, here's how to buy Dogwood Therapeutics stock.

What is DWTX's earnings growth forecast for 2026-2028?

(NASDAQ: DWTX) Dogwood Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33%.

Dogwood Therapeutics's earnings in 2026 is -$25,179,614.On average, 4 Wall Street analysts forecast DWTX's earnings for 2026 to be -$34,118,412, with the lowest DWTX earnings forecast at -$35,590,187, and the highest DWTX earnings forecast at -$32,111,447. On average, 4 Wall Street analysts forecast DWTX's earnings for 2027 to be -$28,074,579, with the lowest DWTX earnings forecast at -$29,221,417, and the highest DWTX earnings forecast at -$26,491,944.

In 2028, DWTX is forecast to generate -$29,244,353 in earnings, with the lowest earnings forecast at -$34,840,920 and the highest earnings forecast at -$22,879,406.

What is DWTX's revenue growth forecast for 2026-2028?

(NASDAQ: DWTX) Dogwood Therapeutics's forecast annual revenue growth rate of 331.05% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.01%.

Dogwood Therapeutics's revenue in 2026 is $100,000.On average, 3 Wall Street analysts forecast DWTX's revenue for 2026 to be $0, with the lowest DWTX revenue forecast at $0, and the highest DWTX revenue forecast at $0. On average, 3 Wall Street analysts forecast DWTX's revenue for 2027 to be $0, with the lowest DWTX revenue forecast at $0, and the highest DWTX revenue forecast at $0.

In 2028, DWTX is forecast to generate $367,408,472 in revenue, with the lowest revenue forecast at $353,034,777 and the highest revenue forecast at $378,226,971.

What is DWTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: DWTX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 21.27%.

What is DWTX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DWTX price target, the average DWTX price target is $12.00, with the highest DWTX stock price forecast at $12.00 and the lowest DWTX stock price forecast at $12.00.

The Wall Street analyst predicted that Dogwood Therapeutics's share price could reach $12.00 by May 19, 2027. The average Dogwood Therapeutics stock price prediction forecasts a potential upside of 1,011.11% from the current DWTX share price of $1.08.

What is DWTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: DWTX) Dogwood Therapeutics's current Earnings Per Share (EPS) is $10.26. On average, analysts forecast that DWTX's EPS will be -$0.89 for 2026, with the lowest EPS forecast at -$0.93, and the highest EPS forecast at -$0.84. On average, analysts forecast that DWTX's EPS will be -$0.73 for 2027, with the lowest EPS forecast at -$0.76, and the highest EPS forecast at -$0.69. In 2028, DWTX's EPS is forecast to hit -$0.77 (min: -$0.91, max: -$0.60).

What is DWTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: DWTX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.